분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-01-09 01:17:02 , Hit : 1463
 Novartis taps into gene editing for next generation drugs


Wed Jan 7, 2015 6:10am EST

* Deals signed with biotech firms Intellia and Caribou

* Swiss drugmaker to use CRISPR gene editing technology

* Intellia tie-up covers CART and hematopoietic stem cells

* Caribou collaboration focused on drug discovery tools

By Ben Hirschler

16x9true  LONDON, Jan 7 (Reuters) - Novartis is diving deeper into the world of gene-based medicine by signing deals with two U.S. biotech companies, giving it access to a powerful new genome editing technology.

The tie-ups with unlisted Intellia Therapeutics and Caribou Biosciences show the Swiss drugmaker's confidence in the potential of so-called CRISPR technology, both for making new medicines and as a research tool.

CRISPR, which stands for clustered regularly interspaced short palindromic repeats, allows scientists to edit the genes of selected cells accurately and efficiently. It has created great excitement since emerging two years ago and is being tipped for a Nobel Prize.

While current gene therapy approaches involve adding genes to affected cells, CRISPR opens up the possibility of correcting those cells' faulty genes in the lab before returning them to the patient.

Translating that promise into new treatments will take many years but Novartis' decision to apply the technology in its research labs is an important endorsement, since the company is the world's largest drugmaker by sales.

It is also a sign the Swiss group intends to be at the forefront of the nascent field, after recently establishing a new cell and gene therapies unit within the company.

Mark Fishman, head of the Novartis Institutes for BioMedical Research (NIBR), said genome editing could open a new branch of medicine, leading to cures for diseases caused by faulty genes.

"We have glimpsed the power of CRISPR tools in our scientific programmes in NIBR and it is now time to explore how to safely extend this powerful technology to the clinic," he said.

The deal with Intellia gives Novartis exclusive rights to develop programmes focused on engineered chimeric antigen receptor T-cells (CARTs) and the right to develop a certain number of targets for editing hematopoietic stem cells.

Novartis is in the vanguard of developing CARTs, which modify patients' immune cells to recognise and destroy cancerous ones, although rivals such as Pfizer are moving in and several biotech companies, including stock market newcomer Juno , are competing hard.

The Caribou collaboration is non-exclusive and focused on using CRISPR as a research tool for drug discovery.

Novartis said it was taking a stake in Caribou and increasing its equity investment in Intellia as part of the deals. Novartis initially invested in Intellia after its launch by Atlas Venture and Caribou three months ago. Financial details were not disclosed by the companies on Wednesday. (Editing by David Clarke)







1027   인간배아 DNA편집을 둘러싼 논란  이성욱 2015/03/17 1023
1026   상처 치유 관련 미스터리 이해  이성욱 2015/03/17 946
1025   First U.S. biosimilar is not considered interchangeable  이성욱 2015/03/11 997
1024   Drug flushes out hidden AIDS virus  이성욱 2015/03/07 1053
1023   숙주 세포와는 별도로 그 활성을 조절하는 HIV  이성욱 2015/03/03 1185
1022   세균이 위협을 기억하는데 도움을 주는 바이러스 절단 효소  이성욱 2015/02/25 1256
1021   iPS세포 '미니 간' 대량생산장치 개발  이성욱 2015/02/23 1042
1020   Paying for gene therapy: are annuities the next big thing?  이성욱 2015/02/22 1021
1019   부모의 특징을 자식에게 전달하는 방식: 박테리아의 DNA  이성욱 2015/02/19 1108
1018   Genzyme, Voyager Launch Up-to-$845M Gene Therapy Collaboration  이성욱 2015/02/14 1267
1017   진화와 질병치료 연구를 진전시킬 새로운 유전 메커니즘  이성욱 2015/02/06 1072
1016   영국 의회, `세 부모 아기` 합법화  이성욱 2015/02/06 1035
1015   텔로미어 연장을 통해 인간 세포의 노화시계를 되돌리는 데 성공  이성욱 2015/02/04 1518
1014   네안데르탈인과 이웃에 살았던 현생인류의 두개골 발견  이성욱 2015/02/03 1095
1013   종양 미세환경에서 T 세포의 작용을 억제하는 PD-1  이성욱 2015/01/30 2622
1012   인류의 역사를 고스란히 보여주는 결핵균의 게놈  이성욱 2015/01/21 1109
1011   역풍 맞은 사이언스 논문 - 암은 대부분 운이 나빠 발생한다?  이성욱 2015/01/21 1241
1010   최초의 바이오시밀러 약물, 미국 시장에 출시  이성욱 2015/01/16 1197
  Novartis taps into gene editing for next generation drugs  이성욱 2015/01/09 1463
1008   저온에서 더 잘 복제되는 감기바이러스  이성욱 2015/01/08 1448

[이전 10개] [1]..[11][12] 13 [14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN